Restructuring and Related Activities |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2026 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Restructuring and Related Activities [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Restructuring and Related Activities Disclosure | COST REDUCTION PLAN During 2025, we announced a plan to reduce our cost structure across operations and selling, general and administrative expenses as we right-size our operations after the sale of our tissue operations (discussed at Note 3). In connection with these activities, we incurred severance expense of $0.6 million associated with this plan, which was recorded in "Other operating charges, net" in the Consolidated Statement of Operations. Changes in our severance liability (included in accounts payable and accrued liabilities on the consolidated balance sheet) for the quarter ended March 31, 2026 and 2025 are as follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||